

RIBOMIC Announces Hit Compounds for COVID-19

TOKYO, August 11, 2020 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced the identification of early-stage "hit compounds" in its development of a new anti-viral aptamer drug targeting the virus that causes COVID-19.

COVID-19 infection starts when the "spike" of the SARS-CoV-2 virus binds to ACE2 protein in the human body. Using the RiboART discovery platform, the RIBOMIC team was able to engineer aptamers that have demonstrated the inhibition of binding between "spike" and ACE2 protein. With these promising results, RIBOMIC will now focus on expanding and optimizing the aptamer molecule portfolio to develop lead drug candidates that will progress into animal and human trials.

To accelerate the potential impact in the fight against COVID-19, RIBOMIC would like to announce a call for leading researchers and clinicians to submit requests to develop candidate drugs and / or treatments which capitalize on the anti-viral effects of these newly discovered aptamers. Please contact us at alliance@ribomic.com for further information.

ABOUT RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company develops aptamer therapeutics, within the fast-growing field of nucleic acid medicine. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other problems. See RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:

RIBOMIC Inc.

Corporate Planning Department

ir.inquiry@ribomic.com